Wird geladen...
A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
Anti-PD1 immunotherapy has emerged as a gold-standard treatment for first- or second-line treatment of stage IV NSCLC, with response rates ranging from 10 to 60%. Strategies to improve the disease control rate are needed. Several reports suggested that debulking surgery enhances anti-tumor immunity....
Gespeichert in:
| Veröffentlicht in: | Sci Rep |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group UK
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858444/ https://ncbi.nlm.nih.gov/pubmed/31729430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-52913-z |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|